Kabi: US Pegfilgrastim Crowd Is An Opportunity For Us, Not A Deterrent
‘We’ve Seen Some Missteps In Supply,’ Kabi Exec Tells Generics Bulletin
In the second part of Generics Bulletin’s exclusive interview with Fresenius Kabi’s senior vice president for biosimilars in the US, Ali Ahmed, he explains why Kabi is relishing the prospect of competing in pegfilgrastim and what the acquisition of mAbxience means for the company’s prospects and vision.
